ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs

计划入组 53 人 · 首次发布于 2025 年 1 月 15 日

Oriental Intervention for Enhanced Neurocognitive Health (ORIENT) Diet in Patients With Intracranial / Carotid Stenosis

计划入组 120 人 · 首次发布于 2023 年 6 月 28 日

Intervention to Help Orient Men to Excel (IN-HOME) Phase II Study

计划入组 360 人 · 首次发布于 2026 年 7 月 15 日

OrienX-010

Romiplostim biosimilar(Geropharma)

antivirals (Chiroscience/Viropharma)

Orient Europharma Co., Ltd.

Taiwan

ORIENT EUROPHARMA PTE LTD

Singapore

Orient Pharma Co., Ltd.

Taiwan

George Medicines Expands Global Reach of Triple-Combination Hypertension Drug GMRx2 Through Strategic Licensing Deals

Benmelstobart Plus Anlotinib Shows Promise in EGFR-Mutated NSCLC After TKI Failure

Aston University Leads €1.2M European Project to Develop Living 'Magnetobots' for Targeted Cancer Theranostics